Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer

Introduction: Osimertinib is a standard treatment for patients with EGFR-mutant NSCLC. Although some osimertinib resistance mechanisms have been identified, nearly 50% of the mechanisms remain to be elucidated. This study was aimed at identifying non-genetic mechanisms underlying osimertinib resista...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Takehiro Tozuka, MD, Rintaro Noro, MD, PhD, Keisuke Yoshida, PhD, Satoshi Takahashi, MD, PhD, Mariko Hirao, MD, Kuniko Matsuda, MD, Yasuhiro Kato, MD, Shinji Nakamichi, MD, PhD, Susumu Takeuchi, MD, PhD, Masaru Matsumoto, MD, PhD, Akihiko Miyanaga, MD, PhD, Shinobu Kunugi, MD, PhD, Kazufumi Honda, DDS, PhD, Jun Adachi, PhD, Masahiro Seike, MD, PhD
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Elsevier 2024-04-01
סדרה:	JTO Clinical and Research Reports
נושאים:	Non–small cell lung cancer EGFR Osimertinib Resistant Src FAK
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S2666364324000389
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!